FDA Science Board Gets Another Routine Extension
Published Date: 6/18/2026
Notice
Summary
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Member Payments and Budgeted Costs
The Science Board has an annual budget of $97,121; estimated annual payments to members are $11,170, and estimated annual reimbursable travel and related expenses for members are $10,760. Federal staff support is estimated at 0.20 FTE costing $51,087, and other internal costs are estimated at $16,822 per year.
Science Board Renewed Through 2028
The FDA renewed its Science Board for an additional two years, with the new charter in effect until June 26, 2028. This keeps the outside expert group that reviews complex scientific and technical issues and advises the Commissioner operating for that period.
Consumer Representative Seat Included
The core voting members may include one technically qualified member identified with consumer interests who is recommended by a consortium of consumer-oriented organizations or other interested persons. That seat is part of the core group of at least 15 voting members.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12166 — Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.
Previous / Next Documents
Previous: 2026-12233 — Vistra Operations Company LLC; Energy Harbor Nuclear Generation LLC; Beaver Valley Power Station, Unit No. 1; License Amendment Request
Vistra Operations Company LLC and Energy Harbor Nuclear Generation LLC want to change the rules for fixing equipment at Beaver Valley Power Station, Unit No. 1. The Nuclear Regulatory Commission is asking the public to comment or request a hearing by mid-July and mid-August 2026. This change lets the plant have more flexible repair times, helping keep things safe without rushing repairs.
Next: 2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.